直接抗病毒药物在丙型肝炎病毒感染合并肝硬化且肝细胞癌已成功治疗患者中疗效高
该前瞻性真实世界研究纳入2015年1月至12月意大利10所三级肝病中心连续收治的1927例丙型肝炎病毒单一感染合并肝硬化和/或肝细胞癌病史患者,评估既往已治疗的肝细胞癌是否影响直接抗病毒药物疗效。意向性分析持续病毒学应答率为95.1%,有既往肝细胞癌者(95.0%)与无既往肝细胞癌者(95.1%)无差异。
要点
- 意向性分析持续病毒学应答率为95.1%。
- 有既往肝细胞癌者持续病毒学应答率95.0%,无既往肝细胞癌者95.1%,两者无差异。
- 持续病毒学应答率在Child A、B、C级间分别为96.3%、86.1%、71.4%(P<0.0001),在基因型间亦有差异(P=0.002)。
核心结论
- 这项大型真实世界研究证明,在肝硬化患者中,直接抗病毒药物的疗效未因肝细胞癌已成功治疗而受损。
主要发现
- 意向性分析持续病毒学应答率为95.1%。
- 持续病毒学应答率在Child A、B、C级间分别为96.3%、86.1%、71.4%(P<0.0001),在基因型间亦有差异(P=0.002)。
- 有既往肝细胞癌者持续病毒学应答率为95.0%,无既往肝细胞癌者为95.1%,两者无差异。
- 多因素分析显示,持续病毒学应答与丙型肝炎病毒基因型、Child分级显著相关。
关键数值与推荐
- 基因1型最常见(67.9%),其次为基因3型(12.4%)、基因2型(11.2%)和基因4型(8.6%)。
- Child A级占88.4%,Child B级占10.9%,Child C级14例(<1%)。
- 腹水和肝性脑病分别发生于10.7%和3.2%的患者,39.3%的患者检出静脉曲张。
- 治疗方案包括:索磷布韦/西美瑞韦15.9%,索磷布韦/来迪派韦33.4%,Viekirax+Exviera方案20.2%,索磷布韦/利巴韦林15.7%,索磷布韦/达拉他韦9.9%,Viekirax 3.4%,含干扰素方案1.3%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The efficacy of direct-acting anti-viral (DAA) therapy in patients with a history of hepatocellular carcinoma (HCC) is unknown. AIM: We prospectively evaluated whether previously treated HCC affects DAA efficacy in a large real-life cohort of cirrhotic patients. METHODS: From January to December 2015 all consecutive HCV mono-infected patients with cirrhosis and/or history of HCC attending 10 Italian tertiary liver centres were enrolled. Baseline characteristics and response to therapy were recorded. 1927 patients were enrolled (mean age: 62.1 ± 10.9 years; 1.205 males). Genotype 1 was the most frequent (67.9%) followed by genotypes 3 (12.4%), 2 (11.2%) and 4 (8.6%). 88.4% and 10.9% of cases were classified Child A and B, respectively, and 14 (<1%) cases were classified Child C. Ascites and hepatic encephalopathy occurred in 10.7% and 3.2% of patients, respectively. Varices were detected in 39.3% of patients. Suboptimal and optimal treatment was prescribed: 15.9% of patients received sofosbuvir/simeprevir, 33.4% sofosbuvir/ledipasvir, 20.2% a Viekirax + Exviera regimen, 15.7% sofosbuvir/ribavirin, 9.9% sofosbuvir/daclatasvir and 3.4% Viekirax; 1.3% of patients received an interferon-based regimen. RESULTS: The sustained virologic response (SVR) rate at intention-to-treat analysis was 95.1%. It differed significantly across Child classes, that is, 96.3%, 86.1% and 71.4% Child A, B and C, respectively (P < 0.0001) and across genotypes (P = 0.002). The SVR rate did not differ between patients with (95.0%) and those without previous HCC (95.1%). At multivariable analysis, SVR was significantly associated with HCV genotype, Child class. CONCLUSION: This large real-life study proves that the efficacy of DAA in cirrhotic patients is not impaired by successfully treated HCC.
引用
- Persico M, Aglitti A, Aghemo A, et al. High efficacy of direct-acting anti-viral agents in hepatitis C virus-infected cirrhotic patients with successfully treated hepatocellular carcinoma. Aliment Pharmacol Ther. 2018. PMID: 29722439. doi:10.1111/apt.14685
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。